ERBB3 and neoplasm: Pertuzumab, the humanized version of the monoclonal antibody 2C4 that binds to the dimerization arm of HER2 [43,52], has also been described as an inhibitor of HER2-HER3 heterodimerization, downstream signaling, and tumor cell growth [53].